Last reviewed · How we verify
Microplegic Solution No. 1
Microplegic Solution No. 1 is a cardioplegic solution used to induce controlled cardiac arrest and protect the heart during cardiac surgery.
Microplegic Solution No. 1 is a cardioplegic solution used to induce controlled cardiac arrest and protect the heart during cardiac surgery. Used for Myocardial protection during cardiac surgery requiring cardiopulmonary bypass.
At a glance
| Generic name | Microplegic Solution No. 1 |
|---|---|
| Sponsor | Washington University School of Medicine |
| Drug class | Cardioplegic solution |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
This solution works by rapidly depolarizing cardiac myocytes through high potassium concentration, inducing asystole (cardiac arrest) that reduces myocardial oxygen demand. The formulation typically contains electrolytes, buffers, and sometimes additives designed to preserve myocardial function and minimize ischemic injury during the period of surgical manipulation when the heart is not perfused.
Approved indications
- Myocardial protection during cardiac surgery requiring cardiopulmonary bypass
Common side effects
- Myocardial ischemic injury
- Arrhythmias post-operatively
- Electrolyte imbalances
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Microplegic Solution No. 1 CI brief — competitive landscape report
- Microplegic Solution No. 1 updates RSS · CI watch RSS
- Washington University School of Medicine portfolio CI